Chem. J. Chinese Universities ›› 2019, Vol. 40 ›› Issue (4): 755.doi: 10.7503/cjcu20180750

• Physical Chemistry • Previous Articles     Next Articles

Highly Efficient MIL-101(Fe) Catalyst for the Preparation of Nopol by the Prins Condensation of β-Pinene and Formaldehyde

JING Run, LU Xinhuan*(), ZHANG Haifu, TAO Peipei, PAN Haijun, HU Ao, ZHOU Dan, XIA Qinghua*()   

  1. Hubei Collaborative Innovation Center for Advanced Organic Chemical Materials & Key Laboratory for the Synthesis and Application of Organic Functional Molecules, Ministry of Education, College of Chemistry Chemical Engineering, Hubei University, Wuhan 430062, China
  • Received:2018-11-07 Online:2019-04-03 Published:2019-01-09
  • Contact: LU Xinhuan,XIA Qinghua E-mail:xinhuan003@hubu.edu.cn;xiaqh518@aliyun.com
  • Supported by:
    † Supported by the National Natural Science Foundation of China(Nos.21503074, 21673069) and the Hubei Province Students Innovation and Entrepreneurship Training Foundation, China(No.201710512045).

Abstract:

Metal organic framework materials MIL-101(Fe) were prepared by hydrothermal synthesis method. All the catalysts were characterized by X-ray diffraction(XRD), Fourier transform infrared spectra(FTIR), thermogravimetric analysis(TG), scanning electron microscopy(SEM), transmission electron microscopy(TEM) and X-ray photoelectron spectroscopy(XPS). Those materials were applied for the catalytic condensation of β-pinene and formaldehyde, and achieved excellent catalytic result. The results indicated that the catalyst synthesis temperature, synthesis time, catalyst amount, solvent, reaction temperature and time have certain effects on the reaction results of condensation reaction. Under similar reaction conditions, MIL-101(Fe)-150-15 catalyst was found to be the most active in the Prins condensation of β-pinene and formaldehyde, for which 97.3% of conversion and 96.7% selectivity are achieved within 8 h at 90 ℃.

Key words: Metal organic framework material, MIL-101(Fe), β-Pinene, Acid catalysis, Nopol

CLC Number: 

TrendMD: